Literature DB >> 25322858

P-cadherin potentiates ligand-dependent EGFR and IGF-1R signaling in dysplastic and malignant oral keratinocytes.

Desseree Lysne1, James Johns1, Andrew Walker1, Rachel Ecker1, Christopher Fowler1, Kathryn R Lawson1.   

Abstract

Oral and oropharyngeal cancer together constitute the sixth most common cancer worldwide, with over 400,000 new cases diagnosed each year. Early detection is paramount, as the 5-year survival rate for these cancers decreases markedly once tumors have become regionally invasive. In many tissues, including oral epithelia, neoplastic progression is accompanied by alterations in expression of the epithelial cell adhesion molecules E-cadherin and P-cadherin. Oral epithelia is one of only a few tissues in which P-cadherin levels have been noted to increase in dysplasia and well-differentiated carcinomas and decrease in advanced malignancies. In the present study, P-cadherin was overexpressed in both dysplastic and malignant oral keratinocytes to characterize the mechanisms by which aberrantly expressed P-cadherin may modulate tumor progression. We found that P-cadherin was able to potentiate ligand-dependent signaling of insulin-like growth factor 1 receptor (IGF-1R) in malignant keratinocytes and epidermal growth factor receptor (EGFR) in dysplastic cells. P-cadherin prolonged activation of the mitogen-activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells. P-cadherin overexpression alone was sufficient to increase steady-state levels of the mesenchymal transcription factor Snail, increase cell motility and also induce morphological changes in dysplastic keratinocytes. Taken together, these data suggest that the aberrantly elevated levels of P-cadherin which occur in early oral tumor development may play a critical role in the augmentation of neoplastic signaling networks and in the further acquisition of aggressive phenotypes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25322858     DOI: 10.3892/or.2014.3545

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

Review 1.  P-cadherin and the journey to cancer metastasis.

Authors:  André Filipe Vieira; Joana Paredes
Journal:  Mol Cancer       Date:  2015-10-06       Impact factor: 27.401

Review 2.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

3.  Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer.

Authors:  Felix Royo; Patricia Zuñiga-Garcia; Verónica Torrano; Ana Loizaga; Pilar Sanchez-Mosquera; Aitziber Ugalde-Olano; Esperanza González; Ana R Cortazar; Laura Palomo; Sonia Fernández-Ruiz; Isabel Lacasa-Viscasillas; Maria Berdasco; James D Sutherland; Rosa Barrio; Amaia Zabala-Letona; Natalia Martín-Martín; Amaia Arruabarrena-Aristorena; Lorea Valcarcel-Jimenez; Alfredo Caro-Maldonado; Jorge Gonzalez-Tampan; Guido Cachi-Fuentes; Manel Esteller; Ana M Aransay; Miguel Unda; Juan M Falcón-Pérez; Arkaitz Carracedo
Journal:  Oncotarget       Date:  2016-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.